antifungal antimicrobial peptides Modern Review,Plant antifungal peptides are generally considered safe for human cells

The relentless battle against fungal infections is entering a new era, powered by the remarkable potential of antifungal antimicrobial peptides (AMPs). These naturally occurring molecules, integral to the innate immune systems of diverse organisms, are emerging as potent and versatile agents capable of combating a wide spectrum of fungal pathogens. Their unique mechanisms of action and favorable safety profiles position them as a promising alternative to conventional antifungal medicines, offering hope against the growing threat of drug-resistant fungi.

Antifungal peptides are fundamentally small cationic peptides that are found in a diverse range of taxa, including bacteria, plants, mammals, and insects. These positively charged small molecules, typically less than 50 amino acids in length, represent a crucial first-line defense against microbial invasions. Their broad-spectrum activity extends beyond bacteria to include enveloped viruses, fungi, and even transformed or cancerous cells. This inherent versatility makes them a compelling area of research for developing novel therapeutic strategies.

The scientific community's interest in antifungal peptides has surged, with numerous studies highlighting their efficacy. Research has demonstrated that antifungal peptides can be developed as antibiotics to control fungal infections in agriculture, showcasing their utility beyond human health. For instance, cystatins are a family of peptides with antifungal properties against significant pathogens like *Candida* and *Aspergillus* species. Furthermore, antimicrobial peptides are found to exhibit broad antimicrobial activity against fungi, underscoring their therapeutic value.

The mechanisms by which antifungal peptides exert their effects are varied and fascinating. One primary mode of action involves the disruption of fungal cell membranes. These peptides can effectively kill pathogenic microorganisms by permeabilizing or creating pores in the cell membrane, leading to leakage of essential cellular contents and ultimately cell death. This direct assault on the fungal cell structure significantly reduces the possibility of developing resistance. Some antifungal peptides are classified by their mode of action, with the first group acting via lysis, which occurs through several distinct mechanisms. Lytic peptides may be employed to target the basic functions of fungal life activities such as cell wall synthesis and intracellular nucleic acid processes.

Beyond membrane disruption, other antifungal peptides operate through intracellular targets, interfering with vital cellular processes. This can include inhibiting enzymes crucial for fungal survival or disrupting DNA replication. From a macroscopic point of view, antifungal peptides inhibit or kill pathogenic fungi by inhibiting mycelial growth, affecting spore germination, or causing other detrimental effects on fungal development. This multifaceted approach to fungal eradication makes them a formidable weapon.

The structural diversity of antifungal peptides is also noteworthy. They may form α-helices, β-sheets, or mixtures thereof, and some are stabilized by cysteine residues. This structural plasticity allows for tailored design and optimization of their antifungal activity. For example, studies have explored the antifungal efficacy of ultrashort β-peptides against *Candida* species, demonstrating potent antifungal properties and broad-spectrum activity.

The therapeutic potential of these peptides is substantial. Researchers are actively investigating various sources and designs. Antifungal peptides from living organisms continue to be a rich source of inspiration, with discoveries being made in diverse flora and fauna. For instance, plant antifungal peptides are generally considered safe for human cells as they target specific microbial components, offering a significant advantage in terms of reduced toxicity. These peptides are part of a plant's defense mechanism, protecting against a wide range of fungal infections, and offer promising avenues for developing new therapeutic agents.

Preclinical and clinical trials are already underway for certain antifungal peptides with anti-*Candida* activity. A notable example is the research involving three peptides (coded as At3, At5 and At10), which exhibited high antifungal activity without significant hemolytic activity in human red blood cells, indicating a favorable safety profile. Another promising development involves cationic dendritic peptides that effectively kill pathogenic microorganisms by disrupting cell membranes.

The development of antifungal peptides is not without its challenges. Optimizing their therapeutic efficacy, ensuring stability against degradation, and developing efficient delivery systems are ongoing areas of research. However, the inherent advantages of antifungal peptides – their unique mechanism of action, low-level toxicity, and potential to overcome existing resistance mechanisms – make them an appealing alternative to standard antifungal medicines.

In conclusion, antifungal antimicrobial peptides represent a rapidly advancing frontier in the fight against fungal diseases. Their natural origins, diverse mechanisms of action, and inherent efficacy have established them as powerful candidates for combating a wide array of fungal infections. As research continues to unravel their complexities and optimize their therapeutic application, these peptides are poised to revolutionize antifungal therapy, offering much-needed hope for patients worldwide.